bgb-a445
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 21, 2020 (NCT04215978)
Timeline
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06029127 | Phase 2 | Oct 23, 2023 | BeOne Medicines |
| NCT05635708 | Phase 2 | Mar 31, 2023 | BeOne Medicines |
| NCT05661955 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | BeOne Medicines |
| NCT04215978 | Phase 1 | Jan 21, 2020 | BeOne Medicines |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 4 | 4 | 2 | 2020 |
1 organizations
Page 1 / 1